Healthcare
Live Price
Offline$260.00
+1.75% today
Window Change
+3.97%
Window
Jun 23, 2025 โ May 14, 2026
Coverage: 226 bars ยท Jun 23, 2025 โ May 14, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bio-Rad Laboratories, Inc. (BIO-B) is a Healthcare stock with a market cap of $7.03B. The stock last traded around $260.00 and up 4.0% across the available one-year price window (Jun 23, 2025 โ May 14, 2026). Baseline metrics include revenue growth of +0.7%, EPS growth of +142.6%, a dividend yield of 0.0%. What stands out right now is revenue +0.7%, EPS +142.6%, free cash flow +40.7% with operating margin 9.2% and ROIC 2.0%. Valuation already assumes a fairly strong business story at P/E 41.1 and price/sales 2.7. Stock Foundry combines BIO-B price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.7% vs +7.6% peer median
Operating Margin
Below sector median
+9.2% vs +19.4% peer median
P/E
Above sector median
41.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +0.7% and EPS at +142.6%, with operating margin around 9.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.9% over the next 5 trading days and finished higher after 0 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 30, 2026 | โ | +0.0% | -12.8% | โ |
2026 Feb 12, 2026 | -6.7% | -12.9% | -11.3% | -9.0% |
2025 Oct 28, 2025 | -771.9% | +0.0% | -5.6% | -3.2% |
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BIO-B
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
BIO-B Max Drawdown
-20.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BIO-B and SPY.
Company Overview
Bio-Rad Laboratories, Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.